Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALDX Aldeyra Therapeutics

Post-Mkt 05-15 17:13:25 EDT

1.68

+0.02

+1.20%

盘后1.66

-0.02-1.11%

16:46 EDT

High1.71	Low1.60	Vol1.31M
Open1.63	D1 Closing1.66	Amplitude6.33%
Mkt Cap101.07M	Tradable Cap81.45M	Total Shares60.16M
T/O2.17M	T/O Rate2.70%	Tradable Shares48.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALDX","market":"US","secType":"STK","nameCN":"Aldeyra Therapeutics","latestPrice":1.68,"timestamp":1778875200000,"preClose":1.66,"halted":0,"volume":1308630,"hourTrading":{"tag":"盘后","latestPrice":1.6614,"preClose":1.68,"latestTime":"16:46 EDT","volume":2874,"amount":4827.7417512,"timestamp":1778878017988,"change":-0.0186,"changeRate":-0.011071,"amplitude":0.011905},"delay":0,"changeRate":0.012048192771084348,"floatShares":48481525,"shares":60162773,"eps":-0.454915,"marketStatus":"Post-Mkt","change":0.02,"latestTime":"05-15 17:13:25 EDT","open":1.63,"high":1.705,"low":1.6,"amount":2165808.953463,"amplitude":0.063253,"askPrice":1.68,"askSize":3382,"bidPrice":1.53,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-0.454915,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1778889600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1399003200000,"exchange":"NASDAQ","adjPreClose":1.66,"preHourTrading":{"tag":"盘前","latestPrice":1.6232,"preClose":1.66,"latestTime":"09:28 EDT","volume":3693,"amount":6107.331248400001,"timestamp":1778851730289,"change":-0.0368,"changeRate":-0.022169,"amplitude":0.03012},"postHourTrading":{"tag":"盘后","latestPrice":1.6614,"preClose":1.68,"latestTime":"16:46 EDT","volume":2874,"amount":4827.7417512,"timestamp":1778878017988,"change":-0.0186,"changeRate":-0.011071,"amplitude":0.011905},"volumeRatio":1.521473,"impliedVol":1.4833,"impliedVolPercentile":0.5339},"requestUrl":"/m/hq/s/ALDX","defaultTab":"news","newsList":[{"id":"2635228098","title":"Aldeyra Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635228098","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635228098?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:01","pubTimestamp":1778619709,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryAldeyra Therapeutics Inc ALDX.OQ reported a quarterly adjusted loss of 6 cents per share for the quarter ended","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P379:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634983134","title":"Aldeyra Therapeutics Inc  expected to post a loss of 13 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634983134","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634983134?lang=en_us&edition=fundamental","pubTime":"2026-05-09 06:40","pubTimestamp":1778280020,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc  expected to post a loss of13cents a share - Earnings Preview Aldeyra Therapeutics Inc ALDX.OQ ALDX.O is expected to  show no change in quarterly revenue when it reports  resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L2U7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631682969","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2631682969","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631682969?lang=en_us&edition=fundamental","pubTime":"2026-04-30 18:00","pubTimestamp":1777543200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·A. O. Smith Corp                                 1Q       .94    6:55 AM. ·Air Prod & Chem                                  2Q      3.06    6:00 AM. ·Altria Grp Inc                                    1Q      1.25    7:00 AM. ·APi Grp Corp                                     1Q       .30    7:30 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","ALNY","AOS","BR","BLDR","BOOM","AXTI","ACCO","AX","BDC","BMY","AME","BAX","BIO.B","CAH","ARDX","CABO","APLS","APD","AUTL","ALHC","AMGN","AIN","BZH","AEM","AXTA","ARVN","AES","ASND","ACA","BBVA","AIG","ATR","ANGX","BAND","BCYC","ALDX","BFLY","BSAC","ASUR","APG","AAPL","AVTX","ATI","ALEC","AJG","BBIO","BIO","ADT","BC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631542057","title":"3 Stocks Estimated To Be Trading Below Intrinsic Value By Up To 35.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631542057","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631542057?lang=en_us&edition=fundamental","pubTime":"2026-04-30 01:08","pubTimestamp":1777482486,"startTime":"0","endTime":"0","summary":"The United States market has remained flat over the last week but has seen a significant rise of 29% over the past 12 months, with earnings forecasted to grow by 16% annually. In this context, identifying stocks that are trading below their intrinsic value can present compelling opportunities for investors seeking to capitalize on potential growth while navigating current market conditions.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/7013000-choice1-main-header/1585186561056","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7013000-choice1-main-header/1585186561056"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/banks/nasdaq-cvbf/cvb-financial/news/3-stocks-estimated-to-be-trading-below-intrinsic-value-by-up-11","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/banks/nasdaq-cvbf/cvb-financial/news/3-stocks-estimated-to-be-trading-below-intrinsic-value-by-up-11","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0889565916.HKD","MC","BK4150","BK4085","ALDX","LU1861217088.USD","LOB","BK4533","PTRN","BUSE","BK4157","LU0320765992.SGD","LU1571399168.USD","BK4139","BK4220","SG9999001440.SGD","CVBF","BK4504","KMB","LU1585245621.USD","BK4588","BK4127","BK4585","LU0109394709.USD","LU1430594728.SGD","LU1878469433.USD","LU0054578231.USD","GLNG","LU2463526074.USD","BK4018","LU0882574055.USD","BK4567","LU1861220207.SGD","BK4548","BK7129","OUST","BK4130","BK4144","MRDN","RHI.AU","BK4211","ALNY","LU0114720955.EUR","SGHC","RHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630173233","title":"Aldeyra Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2630173233","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630173233?lang=en_us&edition=fundamental","pubTime":"2026-04-28 04:11","pubTimestamp":1777320710,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics will hold its annual stockholder meeting in Boston on June 9, 2026.Stockholders will vote on election of Todd C. Brady as Class III director to serve until 2029.Advisory vote scheduled on compensation for named executive officers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 27, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL6cyxPk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630319727","title":"April 2026's Top 3 Stocks That May Be Trading Below Estimated Fair Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2630319727","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630319727?lang=en_us&edition=fundamental","pubTime":"2026-04-28 01:08","pubTimestamp":1777309715,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has remained flat, yet it has experienced a significant 30% increase over the past year with earnings projected to grow by 16% annually. In this environment, identifying stocks that may be trading below their estimated fair value can present opportunities for investors seeking potential long-term gains.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/april-2026s-top-3-stocks-that-may-be-trading-below-estimated","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/april-2026s-top-3-stocks-that-may-be-trading-below-estimated","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BHST","CCB","LU2065731478.USD","BK4548","BK4183","BK4588","LU0114720955.EUR","GLNG","LU0882574055.USD","BK4139","ALLT","FBK","IE0009354923.USD","ZYME","BK4082","GKOS","BK4211","ALNY","OBK","LU1878469433.USD","BK4097","BK4585","FRME","ASIC","BK4107","LU0109394709.USD","LU0320765992.SGD","BK4144","ALDX","LU0889565916.HKD","BUSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629024990","title":"Aldeyra Therapeutics Faces Securities Lawsuit Over Reproxalap Trial Disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2629024990","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629024990?lang=en_us&edition=fundamental","pubTime":"2026-04-23 02:32","pubTimestamp":1776882741,"startTime":"0","endTime":"0","summary":"Aldeyra (ALDX) said its dry eye drug reproxalap had demonstrated broad-based, rapid-onset activity, consistent safety, and statistically significan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/aldeyra-therapeutics-faces-securities-lawsuit-over-reproxalap-trial-disclosures?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/aldeyra-therapeutics-faces-securities-lawsuit-over-reproxalap-trial-disclosures?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALDX","LENZ","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629715067","title":"Aldeyra Therapeutics Announces Upcoming Board Member Departure","url":"https://stock-news.laohu8.com/highlight/detail?id=2629715067","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629715067?lang=en_us&edition=fundamental","pubTime":"2026-04-21 05:38","pubTimestamp":1776721083,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics ( ($ALDX) ) just unveiled an update. On April 20, 2026, Aldeyra Therapeutics, Inc. announced that Board member Martin J. Joyce...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aldeyra-therapeutics-announces-upcoming-board-member-departure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aldeyra-therapeutics-announces-upcoming-board-member-departure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629573779","title":"Aldeyra director Martin Joyce will not stand for re-election at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629573779","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629573779?lang=en_us&edition=fundamental","pubTime":"2026-04-21 05:01","pubTimestamp":1776718886,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics director Martin J. Joyce decided not to stand for re-election at 2026 annual meeting of stockholders.Joyce will remain on board until his term expires at 2026 annual meeting.Decision was not tied to any disagreement with Aldeyra.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDLb3GNgZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628820237","title":"ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky","url":"https://stock-news.laohu8.com/highlight/detail?id=2628820237","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628820237?lang=en_us&edition=fundamental","pubTime":"2026-04-17 21:45","pubTimestamp":1776433511,"startTime":"0","endTime":"0","summary":"NEW YORK, April 17, 2026 — Institutional investors holding positions in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) during the period between Novembe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/aldx-investor-alert-aldeyra-therapeutics-securities-fraud-lawsuit-investors-with-losses-may-seek-to-lead-the-class-action-after-executives-allegedly-omitted-inconsistent-trial-data-levi-korsinsk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/aldx-investor-alert-aldeyra-therapeutics-securities-fraud-lawsuit-investors-with-losses-may-seek-to-lead-the-class-action-after-executives-allegedly-omitted-inconsistent-trial-data-levi-korsinsk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSQ","QQQJ","BK4139","QDTE","DBB",".IXIC","QQQM","TQQQ","QQQY","NDX","QQQE","ONEQ","BK4211","FTEC","MNQmain","NVIW.SI","QID","QQQA","GPIQ","QLD","IYW","ALDX","NQmain","JEPQ","SQQQ","QQQ","ISBC","TQQY","QYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624656216","title":"Aldeyra Therapeutics Sued Over Alleged Misrepresentations About Key Drug Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2624656216","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624656216?lang=en_us&edition=fundamental","pubTime":"2026-04-03 23:34","pubTimestamp":1775230484,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics ($ALDX) told investors its dry eye drug reproxalap was showing strong, consistent results across multiple late-stage trials. F...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/aldeyra-therapeutics-sued-over-alleged-misrepresentations-about-key-drug-trial-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/aldeyra-therapeutics-sued-over-alleged-misrepresentations-about-key-drug-trial-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624541355","title":"Aldeyra Therapeutics Inc - Pays off $15 Mln Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624541355","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624541355?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:27","pubTimestamp":1775075220,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nFWN40K0X6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624413355","title":"Aldeyra Therapeutics repays $15 million, terminates Hercules credit facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2624413355","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624413355?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:25","pubTimestamp":1775075150,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics paid off outstanding borrowings of $15 million under Hercules credit facility on April 1, 2026.Company terminated all remaining commitments under facility, triggering termination pursuant to its terms.Cash, cash equivalents, marketable securities as of Dec. 31, 2025 expected to support operations into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL1bLCX9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621876322","title":"Insider Makes Bold Move on Aldeyra Therapeutics Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2621876322","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621876322?lang=en_us&edition=fundamental","pubTime":"2026-03-21 10:02","pubTimestamp":1774058551,"startTime":"0","endTime":"0","summary":"New insider activity at Aldeyra Therapeutics ( ($ALDX) ) has taken place on March 20, 2026. Director Richard Douglas has significantly increased hi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insider-makes-bold-move-on-aldeyra-therapeutics-stock-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insider-makes-bold-move-on-aldeyra-therapeutics-stock-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620836274","title":"Aldeyra Therapeutics Principal Financial Officer Michael Alfieri acquires USD 7,100 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620836274","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620836274?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:29","pubTimestamp":1773955778,"startTime":"0","endTime":"0","summary":"Michael Alfieri, Principal Financial Officer of Aldeyra Therapeutics, reported a purchase of 5,000 common shares at USD 1.42 per share.Following the transaction, Alfieri beneficially owned 7,500 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 19, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLKSZ8Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","PFG","LU1989772840.SGD","BK4566","LU1989772923.USD","BK4588","BK4139","BK4162","BK4585","ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620225604","title":"What's Going On With Aldeyra Therapeutics Stock On Thursday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620225604","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620225604?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:01","pubTimestamp":1773925260,"startTime":"0","endTime":"0","summary":"Aldeyra stock plunges after FDA rejects its dry eye drug reproxalap, raising concerns over efficacy and future growth prospects.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/19/Doctor-Working-On-Virtual-Touch-Screen-P.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/19/Doctor-Working-On-Virtual-Touch-Screen-P.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/03/51352510/whats-going-on-with-aldeyra-therapeutics-stock-on-thursday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/03/51352510/whats-going-on-with-aldeyra-therapeutics-stock-on-thursday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0029874061.USD","BK4585","BK4139","BK4588","CRL","BK4217","BK4530","SMA","LU0128526141.USD","LU1815336091.USD","IE00BFMHRM44.USD","LU0390134368.USD","LABU","BK4121","LU0757428866.USD","ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620066268","title":"Levi & Korsinsky probes Aldeyra Therapeutics over potential securities fraud claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2620066268","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620066268?lang=en_us&edition=fundamental","pubTime":"2026-03-19 00:36","pubTimestamp":1773851761,"startTime":"0","endTime":"0","summary":"Levi & Korsinsky said it has opened an investigation into Aldeyra Therapeutics over potential violations of U.S. federal securities laws. The firm is reviewing Aldeyra’s 2024 and 2025 statements about the development and regulatory prospects of reproxalap for dry eye disease. It cited an FDA Complete Response Letter dated March 17, 2026 stating that reproxalap had not demonstrated sufficient efficacy. The investigation is examining whether Aldeyra failed to disclose material information about efficacy risks.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL8DCpVx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620237050","title":"Aldeyra Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2620237050","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620237050?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:13","pubTimestamp":1773832380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 07:13 ET (11:13 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620232154","title":"HC Wainwright Downgrades Aldeyra Therapeutics to Neutral From Buy, Adjusts PT to $2 From $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232154","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232154?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:43","pubTimestamp":1773830592,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics (ALDX) has an average rating of buy and mean price target of $8.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620131234","title":"Aldeyra downgraded to Neutral from Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2620131234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620131234?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:12","pubTimestamp":1773828748,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Matthew Caufield downgraded Aldeyra (ALDX) to Neutral from Buy with a price target of $2, down from $10, after the company ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aldeyra-downgraded-to-neutral-from-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aldeyra-downgraded-to-neutral-from-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aldeyra.com;ir.aldeyra.com","stockEarnings":[{"period":"1week","weight":-0.0405},{"period":"1month","weight":-0.0726},{"period":"3month","weight":-0.6856},{"period":"6month","weight":-0.6713},{"period":"1year","weight":-0.235},{"period":"ytd","weight":-0.6795}],"compareEarnings":[{"period":"1week","weight":0.0227},{"period":"1month","weight":0.0773},{"period":"3month","weight":0.0974},{"period":"6month","weight":0.1135},{"period":"1year","weight":0.2733},{"period":"ytd","weight":0.0972}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.071524},{"month":2,"riseRate":0.583333,"avgChangeRate":-0.000501},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.048652},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.015598},{"month":5,"riseRate":0.416667,"avgChangeRate":0.019013},{"month":6,"riseRate":0.333333,"avgChangeRate":0.032526},{"month":7,"riseRate":0.583333,"avgChangeRate":0.052566},{"month":8,"riseRate":0.5,"avgChangeRate":0.050447},{"month":9,"riseRate":0.5,"avgChangeRate":0.169785},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.091942},{"month":11,"riseRate":0.666667,"avgChangeRate":0.079554},{"month":12,"riseRate":0.416667,"avgChangeRate":-0.031913}],"exchange":"NASDAQ","name":"Aldeyra Therapeutics","nameEN":"Aldeyra Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aldeyra Therapeutics(ALDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aldeyra Therapeutics,ALDX,Aldeyra Therapeutics股票,Aldeyra Therapeutics股票老虎,Aldeyra Therapeutics股票老虎国际,Aldeyra Therapeutics行情,Aldeyra Therapeutics股票行情,Aldeyra Therapeutics股价,Aldeyra Therapeutics股市,Aldeyra Therapeutics股票价格,Aldeyra Therapeutics股票交易,Aldeyra Therapeutics股票购买,Aldeyra Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aldeyra Therapeutics(ALDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}